These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
438 related articles for article (PubMed ID: 28162869)
1. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869 [TBL] [Abstract][Full Text] [Related]
2. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition. Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C Eur J Cancer; 2017 Mar; 73():85-92. PubMed ID: 28169047 [TBL] [Abstract][Full Text] [Related]
3. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? Welsh SJ; Rizos H; Scolyer RA; Long GV Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329 [TBL] [Abstract][Full Text] [Related]
4. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy? Kelley MC Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005 [TBL] [Abstract][Full Text] [Related]
5. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644 [TBL] [Abstract][Full Text] [Related]
6. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
7. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019 [TBL] [Abstract][Full Text] [Related]
8. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403 [TBL] [Abstract][Full Text] [Related]
9. Targeting BRAF in melanoma: biological and clinical challenges. MandalĂ M; Voit C Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641 [TBL] [Abstract][Full Text] [Related]
10. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma. Cohen JV; Sullivan RJ Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297 [TBL] [Abstract][Full Text] [Related]
11. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951 [TBL] [Abstract][Full Text] [Related]